CZ300261B6 - Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu - Google Patents

Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu Download PDF

Info

Publication number
CZ300261B6
CZ300261B6 CZ0341197A CZ341197A CZ300261B6 CZ 300261 B6 CZ300261 B6 CZ 300261B6 CZ 0341197 A CZ0341197 A CZ 0341197A CZ 341197 A CZ341197 A CZ 341197A CZ 300261 B6 CZ300261 B6 CZ 300261B6
Authority
CZ
Czechia
Prior art keywords
breast cancer
risk
raloxifene
estrogen
women
Prior art date
Application number
CZ0341197A
Other languages
Czech (cs)
English (en)
Other versions
CZ341197A3 (cs
Inventor
Jay Cohen@Frederic
Ellen Glusman@Joan
Keith Knickerbocker@Rolnald
Thomas Nickelsen@Nikolaus
Janine Scott@Teri
Stephen Eckert@Robert
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ300261(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CZ341197A3 publication Critical patent/CZ341197A3/cs
Publication of CZ300261B6 publication Critical patent/CZ300261B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CZ0341197A 1996-10-30 1997-10-27 Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu CZ300261B6 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10

Publications (2)

Publication Number Publication Date
CZ341197A3 CZ341197A3 (cs) 1998-05-13
CZ300261B6 true CZ300261B6 (cs) 2009-04-01

Family

ID=27268608

Family Applications (2)

Application Number Title Priority Date Filing Date
CZ0341197A CZ300261B6 (cs) 1996-10-30 1997-10-27 Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu
CZ973412A CZ341297A3 (cs) 1996-10-30 1997-10-27 Způsob zlepšení léčby nebo profylaxe rakoviny prsu

Family Applications After (1)

Application Number Title Priority Date Filing Date
CZ973412A CZ341297A3 (cs) 1996-10-30 1997-10-27 Způsob zlepšení léčby nebo profylaxe rakoviny prsu

Country Status (43)

Country Link
US (2) US6303634B1 (enExample)
EP (3) EP0839532B1 (enExample)
JP (2) JPH10147529A (enExample)
CN (2) CN1182590A (enExample)
AP (1) AP971A (enExample)
AR (2) AR010538A1 (enExample)
AT (2) ATE338551T1 (enExample)
AU (3) AU5005697A (enExample)
BE (2) BE1011382A5 (enExample)
BG (1) BG63841B1 (enExample)
BR (1) BR9712703A (enExample)
CA (2) CA2219070C (enExample)
CH (2) CH693820A5 (enExample)
CZ (2) CZ300261B6 (enExample)
DE (2) DE69721692T2 (enExample)
DK (2) DK1369115T3 (enExample)
EA (2) EA006083B1 (enExample)
EE (1) EE03663B1 (enExample)
ES (4) ES2135343A1 (enExample)
FR (2) FR2755014B1 (enExample)
GB (3) GB2318734B (enExample)
GE (1) GEP20032910B (enExample)
GR (2) GR1003189B (enExample)
HU (2) HUP9701777A3 (enExample)
IE (2) IE970772A1 (enExample)
IL (2) IL122026A0 (enExample)
IS (1) IS5035A (enExample)
IT (2) ITMI972434A1 (enExample)
LU (2) LU90157B1 (enExample)
LV (1) LV12353B (enExample)
MY (1) MY121623A (enExample)
NL (2) NL1007386C2 (enExample)
NO (2) NO322468B1 (enExample)
NZ (1) NZ329042A (enExample)
PT (2) PT1369115E (enExample)
RO (1) RO120813B1 (enExample)
SG (2) SG83672A1 (enExample)
SI (3) SI1369115T1 (enExample)
SK (1) SK287047B6 (enExample)
TR (1) TR199900951T2 (enExample)
UA (1) UA46762C2 (enExample)
WO (2) WO1998018325A1 (enExample)
YU (1) YU42397A (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI982733L (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
EP1401446B1 (en) 2001-05-22 2005-02-09 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用
MX2023013107A (es) * 2023-11-06 2025-06-02 Centro De Investig Y De Estudios Avanzados Del I P N Composiciones sinergicas de loratadina-raloxifeno-sorafenib para el tratamiento de cancer hepatico.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0652004A1 (en) * 1993-10-15 1995-05-10 Eli Lilly And Company Methods for treating resistant neoplasms
EP0670162A1 (en) * 1994-03-02 1995-09-06 Eli Lilly And Company Pharmaceutical formulations containing raloxifere, a surfactant and a watersoluble diluent
EP0680758A1 (en) * 1994-05-05 1995-11-08 Eli Lilly And Company Pharmaceutical compositions containing tamoxifen or analogs and raloxifene or analogs
WO1996022771A1 (en) * 1995-01-25 1996-08-01 Eli Lilly And Company Methods of inhibiting environmental estrogens
CZ305398A3 (cs) * 1996-03-26 1999-05-12 Eli Lilly And Company Benzothiaziny, prostředky s jejich obsahem, a způsoby, při kterých se těchto sloučenin využívá

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0652004A1 (en) * 1993-10-15 1995-05-10 Eli Lilly And Company Methods for treating resistant neoplasms
EP0670162A1 (en) * 1994-03-02 1995-09-06 Eli Lilly And Company Pharmaceutical formulations containing raloxifere, a surfactant and a watersoluble diluent
EP0680758A1 (en) * 1994-05-05 1995-11-08 Eli Lilly And Company Pharmaceutical compositions containing tamoxifen or analogs and raloxifene or analogs
WO1996022771A1 (en) * 1995-01-25 1996-08-01 Eli Lilly And Company Methods of inhibiting environmental estrogens
CZ305398A3 (cs) * 1996-03-26 1999-05-12 Eli Lilly And Company Benzothiaziny, prostředky s jejich obsahem, a způsoby, při kterých se těchto sloučenin využívá

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH , vol. 50, issue 14, 1990, cely dokument *
ONCOLOGY , Sept 1988, 2 (9), cely dokument *

Also Published As

Publication number Publication date
CZ341297A3 (cs) 1998-05-13
LU90157B1 (fr) 1998-06-02
GEP20032910B (en) 2003-03-25
MX9708341A (es) 1998-08-30
AU4364897A (en) 1998-05-07
DK1369115T3 (da) 2007-01-02
AU5005197A (en) 1998-05-22
YU42397A (sh) 2000-10-30
EA002054B1 (ru) 2001-12-24
NO322468B1 (no) 2006-10-09
EP0839532A1 (en) 1998-05-06
EE9900162A (et) 1999-12-15
HUP9701777A2 (hu) 1999-06-28
DE69721692D1 (de) 2003-06-12
ES2271476T3 (es) 2007-04-16
SI20107A (sl) 2000-06-30
LV12353A (lv) 1999-10-20
AU5005697A (en) 1998-05-22
SG72765A1 (en) 2000-05-23
US6303634B1 (en) 2001-10-16
JPH10147529A (ja) 1998-06-02
CH691847A5 (fr) 2001-11-15
DK0839532T3 (da) 2003-08-25
PT1369115E (pt) 2006-12-29
ES2135342B1 (es) 2000-05-16
AU731388B2 (en) 2001-03-29
NO974972D0 (no) 1997-10-28
AR013864A1 (es) 2001-01-31
CA2219070C (en) 2007-12-18
JPH10147530A (ja) 1998-06-02
ES2197312T3 (es) 2004-01-01
IL122025A0 (en) 1998-03-10
ES2135343A1 (es) 1999-10-16
NO974972L (no) 1998-05-04
BR9712703A (pt) 1999-10-26
GB2318734B (en) 1999-12-01
WO1998018449A1 (en) 1998-05-07
IS5035A (is) 1999-04-27
FR2756490B1 (fr) 2003-06-20
NL1007387C2 (nl) 1998-05-14
EP1369115B1 (en) 2006-09-06
GR970100408A (el) 1998-06-30
FR2756490A1 (fr) 1998-06-05
BE1011381A5 (fr) 1999-08-03
ATE338551T1 (de) 2006-09-15
UA46762C2 (uk) 2002-06-17
ATE239475T1 (de) 2003-05-15
BE1011382A5 (fr) 1999-08-03
EA199900431A1 (ru) 1999-10-28
NZ329042A (en) 1999-08-30
CN1182590A (zh) 1998-05-27
TR199900951T2 (xx) 1999-07-21
GB2318733A (en) 1998-05-06
HUP9701778A2 (hu) 1999-01-28
AU4364797A (en) 1998-05-07
EA200100716A1 (ru) 2002-06-27
PT839532E (pt) 2003-09-30
DE69736644D1 (de) 2006-10-19
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29
NO974973D0 (no) 1997-10-28
AP9901494A0 (en) 1999-03-31
EP1369115A1 (en) 2003-12-10
CH693820A5 (fr) 2004-02-27
IL122026A0 (en) 1998-03-10
ES2135342A1 (es) 1999-10-16
GR1003189B (el) 1999-09-01
GB9722801D0 (en) 1997-12-24
IE970773A1 (en) 2000-02-09
EE03663B1 (et) 2002-04-15
EP0839533A1 (en) 1998-05-06
DE69721692T2 (de) 2004-03-25
HUP9701777A3 (en) 1999-07-28
SK55999A3 (en) 2000-06-12
LV12353B (en) 2000-02-20
IE970772A1 (en) 2000-02-09
DE69736644T2 (de) 2007-10-25
NL1007386C2 (nl) 1998-05-14
AP971A (en) 2001-05-30
WO1998018325A1 (en) 1998-05-07
SI1369115T1 (sl) 2006-12-31
GB2318734A (en) 1998-05-06
SK287047B6 (sk) 2009-10-07
BG103369A (en) 2000-05-31
HK1010495A1 (en) 1999-06-25
FR2755014A1 (fr) 1998-04-30
US20020019418A1 (en) 2002-02-14
EA006083B1 (ru) 2005-08-25
IL122025A (en) 2003-01-12
EP0839532B1 (en) 2003-05-07
MY121623A (en) 2006-02-28
CZ341197A3 (cs) 1998-05-13
GR970100409A (el) 1998-06-30
FR2755014B1 (fr) 1999-02-05
CA2219070A1 (en) 1998-04-30
LU90158B1 (fr) 1998-06-02
MX9708340A (es) 1998-08-30
ITMI972433A1 (it) 1999-04-29
GB9911557D0 (en) 1999-07-21
AR010538A1 (es) 2000-06-28
HUP9701778A3 (en) 1999-06-28
SG83672A1 (en) 2001-10-16
BG63841B1 (bg) 2003-03-31
GB9722796D0 (en) 1997-12-24
SI0839532T1 (en) 2003-10-31
ITMI972434A1 (it) 1999-04-29
IT1298470B1 (it) 2000-01-10
CN1182591A (zh) 1998-05-27
RO120813B1 (ro) 2006-08-30
CA2219377A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
JP2749247B2 (ja) ベンゾチオフェン類を含有する医薬製剤
CZ341197A3 (cs) Způsoby prevence karcinomu prsu
RU2203060C2 (ru) Способ профилактики рака молочной железы
US20040167170A1 (en) Methods of preventing breast cancer
KR100522646B1 (ko) 유방암의예방방법
AU2004231254B8 (en) Methods of preventing breast cancer
HUT76890A (en) Use of benzotiophene derivatives for producing phamaceutical compositions against endometrial cancer
MXPA97008341A (en) Procedures to prevent the cancer of m
IL152080A (en) Use of raloxifene or pharmaceutically acceptable salts or solvates thereof in the preparation of a medicament for preventing breast cancer
HK1010493A (en) Methods of preventing breast cancer by the administration of raloxifene
TW586942B (en) A pharmaceutical composition for use in preventing breast cancer

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20131027